Our Hyper-crosslinked Carbohydrate Polymer (HCCP) scaffold is designed to support 3D organoid growth for drug screening, toxicology studies, and regenerative medicine. It offers a scalable, xeno-free platform with consistent quality and defined composition.

With a market projected to exceed $3 billion by 2030 and growing demand from NIH-backed organoid research, this product is positioned for strong adoption. A prototype is already in use through early academic collaborations, with a full launch planned for 2026.

Preclinical data includes tumor heterogeneity studies, brain, heart, kidney, and stem cell organoids with clinical potential, and 3D hepatocyte cultures for toxicology.

Projected peak sales are $50 million annually.